Revenue Projections - BRUKINSA's global revenues for BTK inhibitors were approximately $12 billion in 2025 and are projected to exceed $15 billion by 2028[36]. - TEVIMBRA's global revenues for PD-1/PD-L1 antibody medicines exceeded $50 billion in 2025, with the China PD-1/L1 market at approximately $4 billion[43]. Regulatory Approvals - BRUKINSA has received approvals in five indications and is approved in 77 markets, with reimbursement in 58 markets[38]. - TEVIMBRA has received regulatory approvals in multiple geographies, including the EU and 23 countries across North America, Europe, and Asia Pacific[45]. - XGEVA is approved in over 70 countries and received conditional approval in China for GCTB in May 2019, with regular approval granted later[49]. - BLINCYTO has been approved in 60 countries for acute lymphoblastic leukemia and was commercialized in China starting August 2021[50]. - KYPROLIS was approved in China for R/R multiple myeloma in July 2021 and included in the NRDL in March 2023[51]. - SYLVANT was approved in China in December 2021 for idiopathic multicentric Castleman disease and included in the NRDL starting January 2024[53]. - QARZIBA received conditional approval in China for high-risk neuroblastoma and began commercialization in December 2021[54]. - POBEVCY is a biosimilar to Avastin and is approved in China for multiple cancer treatments[55]. - POBEVCY was launched in late 2021 for treating advanced cancers and has been approved for commercialization in China, including Hong Kong, Macau, and Taiwan[56]. - BAITUOWEI, the world's first approved microsphere formulation of Goserelin, was approved in June 2023 for prostate cancer and in September 2023 for breast cancer, with inclusion in the NRDL planned for 2024[57]. - TEVIMBRA has been included in the NRDL effective January 1, 2026, for multiple indications, including treatment for NSCLC and HCC[62]. - Sonrotoclax received approval in China for adult patients with R/R MCL and CLL/SLL who have received at least one systemic therapy[82]. Clinical Development - The global BRUKINSA clinical development program includes over 7,900 patients enrolled across more than 30 countries and regions, with BRUKINSA approved in over 75 markets and more than 265,000 patients treated globally[73]. - Zanubrutinib has shown superior progression-free survival in R/R CLL compared to IMBRUVICA, reinforcing its best-in-class profile[72]. - The SEQUOIA study results demonstrated sustained clinical benefit with BRUKINSA in frontline CLL, both as monotherapy and in combination with venetoclax[74]. - The final analysis of the randomized Phase 2 ROSEWOOD study confirmed the favorable risk-benefit profile of zanubrutinib plus obinutuzumab, with improved objective response rate (ORR) and complete response (CR) rate over time[76]. - The company is pursuing regulatory approvals for BRUKINSA globally, with ongoing Phase 3 studies in multiple indications[80]. - The company continues to evaluate zanubrutinib in combination studies for MCL, MZL, and CLL/SLL, including a Phase 3 trial with sonrotoclax[80]. - Sonrotoclax plus obinutuzumab demonstrated encouraging antitumor activity with high rates of blood uMRD4 in patients with TN CLL/SLL, with no discontinuations or deaths due to TEAEs[85]. - In a Phase 1b/2 study, sonrotoclax combination therapy achieved an 84% overall response rate (ORR) and a 32% complete response (CR) rate in heavily pretreated patients with t(11;14)-positive R/R MM[86]. - A Phase 2 expansion cohort for BGB-16673 is enrolling in R/R CLL after BCL2 and BTK inhibitor therapy, with potential accelerated approval filing in 2026[90]. Manufacturing and Capacity - The manufacturing facility in Suzhou has an annual production capacity of approximately 600 million tablets and capsules, operational for clinical supply since early 2024 and commercial supply since May 2025[124]. - The Guangzhou facility has completed Phase 3 capacity qualification, increasing total biologics manufacturing capacity to approximately 64,000 liters, with a new ADC manufacturing facility commissioned in April 2024[125]. - The U.S. manufacturing facility in New Jersey has over 1 million square feet of developable real estate and 8,000 liters of large molecule biologics manufacturing capacity, now fully operational[123]. - The Guangzhou facility's biologics manufacturing capacity will increase to approximately 65,000 liters following the recent expansion, supporting pipeline development[125]. Collaboration and Intellectual Property - The company has entered into a collaboration agreement with Amgen, co-funding global development costs up to $1.25 billion for oncology products, sharing profits and losses equally in the collaboration territory[131]. - As of February 13, 2026, the company owns 68 issued U.S. patents and 72 issued China patents, with additional pending applications in various regions[140]. - ZIIHERA's key patents in China are set to expire between 2031 and 2039, with multiple compositions and methods of use covered[143]. - BLINCYTO's method of use patent in China expires in 2029, while its combination use patent extends to 2031[143]. - The company retains responsibility for defending and enforcing patents for in-licensed products, while partners like Zymeworks and Amgen have similar obligations[143]. Market and Pricing Dynamics - Coverage and reimbursement for approved products can vary significantly among third-party payors, affecting sales and pricing strategies[184]. - Third-party payors are increasingly challenging the cost-effectiveness and medical necessity of medical products, which may require expensive pharmacoeconomic studies for coverage and reimbursement[186]. - The proposed pricing for drugs in foreign countries must often be approved before marketing, with the EU allowing member states to control prices and reimbursement, leading to historically lower prices compared to the U.S.[187]. - The Affordable Care Act (ACA) includes provisions that may reduce drug profitability, such as increased Medicaid rebates and mandatory discounts for Medicare beneficiaries[188]. - The Bipartisan Budget Act of 2018 increased the point-of-sale discount for Medicare Part D from 50% to 70%, impacting pharmaceutical manufacturers' revenues[189]. - The Inflation Reduction Act of 2022 reduces out-of-pocket spending for Medicare Part D beneficiaries from $7,050 to $2,000 starting in 2025, affecting drug pricing and manufacturer liabilities[190]. - The proposed GUARD Model aims to test alternative Medicare rebate calculations based on international pricing metrics, potentially impacting drug costs from January 1, 2027[192]. - The 340B drug pricing program has seen changes that may expand patient access to discounted medications, affecting manufacturers' pricing strategies[195]. - State-level regulations are increasingly controlling pharmaceutical pricing, including Upper Payment Limits (UPLs) on high-priced drugs, which may pressure future revenues[196]. Compliance and Legal Considerations - The federal Anti-Kickback Statute imposes significant penalties for violations, impacting marketing practices and relationships with healthcare providers[197]. - State privacy laws may impose greater protections than HIPAA, complicating compliance and increasing litigation risks for the company[198]. - The company must comply with various federal and state healthcare laws, which may involve substantial costs and could lead to investigations or sanctions if practices are deemed non-compliant[203]. - The FDA requires extensive data demonstrating quality, safety, and efficacy before a new drug can be marketed, involving multiple phases of clinical trials[152][154]. - The FDA may issue a complete response letter if an NDA or BLA does not meet approval criteria, which could require additional data or clinical trials[164]. - Products receiving regulatory approval may have limitations on specific diseases and dosages, affecting their commercial value[165]. European Market Regulations - The EMA coordinates the scientific evaluation and monitoring of medicinal products in the EU, and the centralized procedure for marketing authorization is compulsory for certain products[204][212]. - The centralized procedure allows for marketing authorizations valid throughout the EU, with a maximum evaluation timeframe of 210 days, which may extend due to additional information requests[214]. - New medicinal products containing a new active substance benefit from eight years of data exclusivity, with a potential extension to 11 years if new therapeutic indications are approved[215]. - Orphan medicinal product designation may be granted for products intended for rare conditions affecting not more than five in 10,000 persons in the EU, providing significant clinical benefits[217].
BEIGENE(ONC) - 2025 Q4 - Annual Report